---
document_datetime: 2025-11-23 08:03:10
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/entacapone-teva.html
document_name: entacapone-teva.html
version: success
processing_time: 0.1217478
conversion_datetime: 2025-12-26 12:13:52.462279
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Entacapone Teva

[RSS](/en/individual-human-medicine.xml/65891)

##### Authorised

This medicine is authorised for use in the European Union

entacapone

Medicine

Human

Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Entecapone Teva](#more-information-on-entecapone-teva-1133)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Entacapone Teva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Entacapone Teva.

Expand section

Collapse section

## What is Entacapone Teva?

Entacapone Teva is a medicine that contains the active substance entacapone. It is available as tablets (200 mg).

Entacapone Teva is a 'generic medicine'. This means that Entacapone Teva is similar to a 'reference medicine' already authorised in the European Union (EU) called Comtess.

## What is Entacapone Teva used for?

Entacapone Teva is used to treat patients with Parkinson's disease. Parkinson's disease is a progressive brain disorder that causes shaking, slow movement and muscle stiffness. Entacapone Teva is used together with levodopa (either a combination of levodopa and benserazide or a combination of levodopa and carbidopa) when the patient is having 'fluctuations' towards the end of the period between two doses of their medication. Fluctuations happen when the effects of the medication wear off and symptoms re-emerge. They are linked with a reduction in the effects of levodopa, when the patient experiences sudden switches between being 'on' and able to move, and being 'off' and having difficulties moving about. Entacapone Teva is used when these fluctuations cannot be treated with the standard levodopa-containing combination alone.

The medicine can only be obtained with a prescription.

## How is Entacapone Teva used?

Entacapone Teva is only used in combination either with levodopa and benserazide or with levodopa and carbidopa. It is taken as one tablet with each dose of the other medicine, up to a maximum of 10 tablets a day. When patients first add Entacapone Teva to their existing medication, they may need to take a lower daily dose of levodopa, either by changing how often they take it, or by reducing the amount of levodopa taken in each dose. Entacapone Teva can only be used with conventional combinations of levodopa. It should not be used with combinations that are 'modified release' (when the levodopa is released slowly over a few hours).

## How does Entacapone Teva work?

In patients with Parkinson's disease, the cells in the brain that produce the neurotransmitter dopamine begin to die and the amount of dopamine in the brain decreases. The patients then lose their ability to control their movements reliably. The active substance in Entacapone Teva, entacapone, works to restore the levels of dopamine in the parts of the brain that control movement and coordination. It only works when it is taken with levodopa, a copy of the neurotransmitter dopamine that can be taken by mouth. Entacapone blocks an enzyme that is involved in the breakdown of levodopa in the body called catechol-O-methyl transferase (COMT). As a result, levodopa remains active for longer. This helps to improve the symptoms of Parkinson's disease, such as stiffness and slowness of movement.

## How has Entacapone Teva been studied?

Because Entacapone Teva is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Comtess. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefits and risks of Entacapone Teva?

Because Entacapone Teva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why has Entacapone Teva been approved?

The CHMP concluded that, in accordance with EU requirements, Entacapone Teva has been shown to have comparable quality and to be bioequivalent to Comtess. Therefore, the CHMP's view was that, as for Comtess, the benefit outweighs the identified risk. The Committee recommended that Entacapone Teva be given marketing authorisation.

## Other information about Entacapone Teva

The European Commission granted a marketing authorisation valid throughout the European Union for Entacapone Teva on 18 February 2011.

For more information about treatment with Entacapone Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Entacapone Teva : EPAR - Summary for the public

Reference Number: EMA/CHMP/784611/2010

English (EN) (76.25 KB - PDF)

**First published:** 03/03/2011

**Last updated:** 28/01/2016

[View](/en/documents/overview/entacapone-teva-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-817)

български (BG) (102.91 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/01/2016

[View](/bg/documents/overview/entacapone-teva-epar-summary-public_bg.pdf)

español (ES) (75.42 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/01/2016

[View](/es/documents/overview/entacapone-teva-epar-summary-public_es.pdf)

čeština (CS) (97.76 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/01/2016

[View](/cs/documents/overview/entacapone-teva-epar-summary-public_cs.pdf)

dansk (DA) (73.98 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/01/2016

[View](/da/documents/overview/entacapone-teva-epar-summary-public_da.pdf)

Deutsch (DE) (77.18 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/01/2016

[View](/de/documents/overview/entacapone-teva-epar-summary-public_de.pdf)

eesti keel (ET) (73.89 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/01/2016

[View](/et/documents/overview/entacapone-teva-epar-summary-public_et.pdf)

ελληνικά (EL) (104.2 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/01/2016

[View](/el/documents/overview/entacapone-teva-epar-summary-public_el.pdf)

français (FR) (76.44 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/01/2016

[View](/fr/documents/overview/entacapone-teva-epar-summary-public_fr.pdf)

hrvatski (HR) (90.1 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/01/2016

[View](/hr/documents/overview/entacapone-teva-epar-summary-public_hr.pdf)

italiano (IT) (75.45 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/01/2016

[View](/it/documents/overview/entacapone-teva-epar-summary-public_it.pdf)

latviešu valoda (LV) (100.82 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/01/2016

[View](/lv/documents/overview/entacapone-teva-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (95.58 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/01/2016

[View](/lt/documents/overview/entacapone-teva-epar-summary-public_lt.pdf)

magyar (HU) (95.52 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/01/2016

[View](/hu/documents/overview/entacapone-teva-epar-summary-public_hu.pdf)

Malti (MT) (99.54 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/01/2016

[View](/mt/documents/overview/entacapone-teva-epar-summary-public_mt.pdf)

Nederlands (NL) (75.26 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/01/2016

[View](/nl/documents/overview/entacapone-teva-epar-summary-public_nl.pdf)

polski (PL) (100.47 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/01/2016

[View](/pl/documents/overview/entacapone-teva-epar-summary-public_pl.pdf)

português (PT) (78.12 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/01/2016

[View](/pt/documents/overview/entacapone-teva-epar-summary-public_pt.pdf)

română (RO) (96.99 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/01/2016

[View](/ro/documents/overview/entacapone-teva-epar-summary-public_ro.pdf)

slovenčina (SK) (97.88 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/01/2016

[View](/sk/documents/overview/entacapone-teva-epar-summary-public_sk.pdf)

slovenščina (SL) (89.25 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/01/2016

[View](/sl/documents/overview/entacapone-teva-epar-summary-public_sl.pdf)

Suomi (FI) (76.1 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/01/2016

[View](/fi/documents/overview/entacapone-teva-epar-summary-public_fi.pdf)

svenska (SV) (74.41 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/01/2016

[View](/sv/documents/overview/entacapone-teva-epar-summary-public_sv.pdf)

## Product information

Entacapone Teva : EPAR - Product Information

English (EN) (379.57 KB - PDF)

**First published:** 03/03/2011

**Last updated:** 28/09/2021

[View](/en/documents/product-information/entacapone-teva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-167)

български (BG) (415.99 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/09/2021

[View](/bg/documents/product-information/entacapone-teva-epar-product-information_bg.pdf)

español (ES) (339.15 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/09/2021

[View](/es/documents/product-information/entacapone-teva-epar-product-information_es.pdf)

čeština (CS) (355.58 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/09/2021

[View](/cs/documents/product-information/entacapone-teva-epar-product-information_cs.pdf)

dansk (DA) (327.7 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/09/2021

[View](/da/documents/product-information/entacapone-teva-epar-product-information_da.pdf)

Deutsch (DE) (357.25 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/09/2021

[View](/de/documents/product-information/entacapone-teva-epar-product-information_de.pdf)

eesti keel (ET) (352.24 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/09/2021

[View](/et/documents/product-information/entacapone-teva-epar-product-information_et.pdf)

ελληνικά (EL) (422.57 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/09/2021

[View](/el/documents/product-information/entacapone-teva-epar-product-information_el.pdf)

français (FR) (360.26 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/09/2021

[View](/fr/documents/product-information/entacapone-teva-epar-product-information_fr.pdf)

hrvatski (HR) (393.56 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/09/2021

[View](/hr/documents/product-information/entacapone-teva-epar-product-information_hr.pdf)

íslenska (IS) (342.23 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/09/2021

[View](/is/documents/product-information/entacapone-teva-epar-product-information_is.pdf)

italiano (IT) (358.13 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/09/2021

[View](/it/documents/product-information/entacapone-teva-epar-product-information_it.pdf)

latviešu valoda (LV) (384.74 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/09/2021

[View](/lv/documents/product-information/entacapone-teva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (382.31 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/09/2021

[View](/lt/documents/product-information/entacapone-teva-epar-product-information_lt.pdf)

magyar (HU) (392.05 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/09/2021

[View](/hu/documents/product-information/entacapone-teva-epar-product-information_hu.pdf)

Malti (MT) (400.06 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/09/2021

[View](/mt/documents/product-information/entacapone-teva-epar-product-information_mt.pdf)

Nederlands (NL) (377.97 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/09/2021

[View](/nl/documents/product-information/entacapone-teva-epar-product-information_nl.pdf)

norsk (NO) (345.83 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/09/2021

[View](/no/documents/product-information/entacapone-teva-epar-product-information_no.pdf)

polski (PL) (383.98 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/09/2021

[View](/pl/documents/product-information/entacapone-teva-epar-product-information_pl.pdf)

português (PT) (375.91 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/09/2021

[View](/pt/documents/product-information/entacapone-teva-epar-product-information_pt.pdf)

română (RO) (376.7 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/09/2021

[View](/ro/documents/product-information/entacapone-teva-epar-product-information_ro.pdf)

slovenčina (SK) (411.01 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/09/2021

[View](/sk/documents/product-information/entacapone-teva-epar-product-information_sk.pdf)

slovenščina (SL) (366.91 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/09/2021

[View](/sl/documents/product-information/entacapone-teva-epar-product-information_sl.pdf)

Suomi (FI) (337.08 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/09/2021

[View](/fi/documents/product-information/entacapone-teva-epar-product-information_fi.pdf)

svenska (SV) (386.14 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

28/09/2021

[View](/sv/documents/product-information/entacapone-teva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0018 10/09/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Entacapone Teva : EPAR - All Authorised presentations

English (EN) (21.12 KB - PDF)

**First published:** 03/03/2011

**Last updated:** 03/03/2011

[View](/en/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-311)

български (BG) (52.7 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

03/03/2011

[View](/bg/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_bg.pdf)

español (ES) (21.77 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

03/03/2011

[View](/es/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (49.69 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

03/03/2011

[View](/cs/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (21.36 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

03/03/2011

[View](/da/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (21.41 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

03/03/2011

[View](/de/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (21.63 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

03/03/2011

[View](/et/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (52.17 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

03/03/2011

[View](/el/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_el.pdf)

français (FR) (21.59 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

03/03/2011

[View](/fr/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (26.95 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

03/03/2011

[View](/hr/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (21.63 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

03/03/2011

[View](/is/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (21.2 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

03/03/2011

[View](/it/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (49.37 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

03/03/2011

[View](/lv/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (49.93 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

03/03/2011

[View](/lt/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (50.69 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

03/03/2011

[View](/hu/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (49.95 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

03/03/2011

[View](/mt/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (21.16 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

03/03/2011

[View](/nl/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (25.32 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

03/03/2011

[View](/no/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_no.pdf)

polski (PL) (35.23 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

03/03/2011

[View](/pl/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_pl.pdf)

português (PT) (21.73 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

03/03/2011

[View](/pt/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_pt.pdf)

română (RO) (49.42 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

03/03/2011

[View](/ro/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (49.98 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

03/03/2011

[View](/sk/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (36.62 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

03/03/2011

[View](/sl/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (21.4 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

03/03/2011

[View](/fi/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (21.52 KB - PDF)

**First published:**

03/03/2011

**Last updated:**

03/03/2011

[View](/sv/documents/all-authorised-presentations/entacapone-teva-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Entacapone Teva Active substance entacapone International non-proprietary name (INN) or common name entacapone Therapeutic area (MeSH) Parkinson Disease Anatomical therapeutic chemical (ATC) code N04BX02

### Pharmacotherapeutic group

Anti-Parkinson drugs

### Therapeutic indication

Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.

## Authorisation details

EMA product number EMEA/H/C/002075

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva Pharma B.V.

Computerweg 10

Opinion adopted 18/11/2010 Marketing authorisation issued 18/02/2011 Revision 10

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Entacapone Teva : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (157.24 KB - PDF)

**First published:** 07/02/2013

**Last updated:** 28/09/2021

[View](/en/documents/procedural-steps-after/entacapone-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Entacapone Teva : EPAR - Public assessment report

Adopted

Reference Number: EMA/52316/2011

English (EN) (289.92 KB - PDF)

**First published:** 03/03/2011

**Last updated:** 03/03/2011

[View](/en/documents/assessment-report/entacapone-teva-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Entacapone Teva

Adopted

Reference Number: EMA/CHMP/659548/2010

English (EN) (130.18 KB - PDF)

**First published:** 26/11/2010

**Last updated:** 26/11/2010

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-entacapone-teva_en.pdf)

#### More information on Entecapone Teva

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-44)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 28/09/2021

## Share this page

[Back to top](#main-content)